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Exome sequencing technologies are con-
stantly evolving, with exome capture
systems covering more coding bases, and
the continual development of improved
alignment and variant-calling pro-
grammes. At the same time, new genes are
frequently being implicated in Mendelian
genetic disease. In many cases, therefore,
the generation of extra coverage, updating
of alignment and variant calling tools and
regular inspection for novel gene-disease
associations emerging in the literature will
yield a diagnosis that was not found in the
initial analysis.
The rates of diagnosis with exome
sequencing range from 25% to 40%.1
The diagnosis rate depends on various
factors including how patients are
selected, the degree of genetic prescreen-
ing, the age and ancestry of the popula-
tion and what is deﬁned as a probable
diagnosis. Some of those that remain
undiagnosed will not, in fact, have a
Mendelian genetic disorder, for example,
those with disorders due to mutations in
mitochondrial genes, somatic mutations
and those with oligogenic or more
complex genetic disorders. However,
there are many ways that patients with a
relevant Mendelian pathogenic genetic
variant may not obtain a diagnosis in the
initial analysis. These can be divided into
two broad classes.
1. The variant is not identiﬁed. The sim-
plest reason for patients remaining
undiagnosed is that the pathogenic
variant is not identiﬁed. This may be
because it is in a region not included
in the exome sequence, for example,
intronic or intergenic variants, or
because that site is just poorly covered
in that individual due to ﬂuctuations
in coverage.2 Other variant sites may
be well covered but the variants them-
selves are not easily discoverable by
current bioinformatic tools, for
example, repeat polymorphisms and
structural variants, or single nucleotide
variants or small insertion/deletion
polymorphisms in regions of local
genomic complexity.
2. The variant is not recognised as patho-
genic. This may be for a number of
reasons. First, the variant itself may
appear innocuous. We all contain in
our genomes hundreds of gene-
damaging variants,3 and very rare var-
iants that do not appear in any data-
bases, so distinguishing between those
that are and are not contributing to
disease is the main hurdle in diagnostic
exome sequencing. The obvious candi-
dates are very rare, clearly damaging
mutations such as nonsense or frame-
shift variants, or variants that affect
splicing. Dominant disease is often
much easier because many of the
causal variants are de novo, whereas
there can be a lot of candidate com-
pound heterozygotes for autosomal
recessives. Sometimes pathogenic
genetic variants are not obviously
damaging, for example, synonymous
variants can sometimes cause disease
by affecting splicing. But because most
synonymous genetic variants are
benign, they will often appear in
disease genes and will largely be
ignored when interpreting a genome
for diagnostic purposes. Alternatively,
a recognisably damaging pathogenic
variant may be ﬁltered out because it
appears in unaffected parents or
public databases of unaffected indivi-
duals due to reduced penetrance, or
based on somatic variant calls.
Other variants that may not be recog-
nised as pathogenic are those that are not
in known disease genes. We are increas-
ingly able to recognise genes that are likely
to be pathogenic, using measures of their
‘intolerance’ to damaging variation such as
the Residual Variation Intolerance Score
(RVIS) score4 and the probability of being
Loss-of-function Intolerant (pLI) score in
Exome Aggregation Consortium (ExAC), a
publicly available database of variants from
over 60 000 sequenced exomes.3 However,
if you only have a single patient with a
damaging mutation in a gene previously
unlinked to disease, it is very unlikely that
patient would receive a genetic diagnosis
based on this, however intolerant that gene
is predicted to be. In these situations, the
gene should be regularly investigated using
databases such as GeneMatcher (https://
genematcher.org/) and PhenomeCentral
(https://phenomecentral.org/) available
through the Matchmaker Exchange (http://
www.matchmakerexchange.org/) to see if
other patients have been reported with a
similar phenotype with a variant in the
same gene. A recent report indicated that
10% of patients with an initially negative
whole exome sequence (WES) were subse-
quently diagnosed based just on inspection
of novel disease-association literature.5
To illustrate this, we re-analysed the 6
unsolved trios from our 2012 study of 12
trios with unidentiﬁed presumed
Mendelian disorders.6 Of 12 trios with
varied presentations who had already
undergone thorough diagnostic workups,
we originally identiﬁed a complete genetic
diagnosis for 6, and a partial diagnosis (in
which a gene mutation explains part but
probably not all of the phenotype) for 1.
At the time of our original report, the
sequence reads were aligned to genome
build 36, and variants were called with
SAMtools.7 After realignment to build 37,
and variant calling with Genome Analysis
ToolKit (GATK),8 two new diagnoses were
made. In trio 8, a known pathogenic
variant, R246C (rs122445105), was found
in ATRX which causes the X linked reces-
sive α-thalassaemia/mental retardation syn-
drome. The maternally inherited variant
was hemizygous in the patient. The
patient’s phenotypic features of growth
retardation, profound intellectual disabil-
ity, hypospadias and dysmorphic facial fea-
tures are a good phenotypic ﬁt for ATRX,
although he does not have anaemia, which
would have increased clinical suspicion of
this disorder and the bicoronal craniosy-
nostosis that he was born with remains
unexplained. In trio 12, a heterozygous de
novo nonsense mutation (chr16:307486
91C>T, R2444*) was identiﬁed in SRCAP,
which ﬁts the patient’s clinical diagnosis of
Floating-Harbor syndrome. Although this
gene was speciﬁcally searched for patho-
genic variants before realignment, nothing
of interest was observed based on the
earlier alignment and variant calling.
Adding coverage for the remaining
unsolved trios revealed that patient 10
had a heterozygous de novo frameshift
variant (chr6:157454179CAAAG>C,
R798TfsTer46) in ARID1B, a mutation
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that would be expected to result in
Cofﬁn-Siris syndrome, a good clinical ﬁt.
The variant was not initially identiﬁed
because the WES coverage and alignment
at this site was poor.
Inspection of recent literature9 indicates
that a de novo splice-acceptor mutation in
HNRNPU in patient 6 that was classiﬁed
as an ‘interesting ﬁnding’ in the original
report can now be considered to be a
likely cause of (at least) the patient’s epi-
lepsy and intellectual disability.
Finally, we note that in our original
report we identiﬁed compound heterozy-
gous loss-of-function variants in NGLY1
in a patient who had a phenotype resem-
bling a congenital disorder of glycosyla-
tion. The gene was not a known disease
gene, but because the clinical phenotype
was biologically consistent with NGLY1
dysfunction and the patient had a near-
absence of NGLY1 protein expression, the
ﬁnding was reported back to the family as
likely causal. Since then (largely as a result
of efforts by the parents), NGLY1 deﬁ-
ciency has become a recognised genetic
disorder and many other patients have
been diagnosed.10 In WES diagnostic
pipelines that focus only on known
disease genes, this ﬁnding would have
been missed, emphasising the value of
careful interpretation in the absence of
known disease associations.
Of interest, the only patient who
remained without a diagnosis was the
only patient of African ancestry. Patient 9
has a number of new, damaging genotypes
in genes that are intolerant to genetic vari-
ation but not yet associated with disease,
including FAM134C and MSI1, which
may yet prove to be causal. Because WES
control databases often include relatively
small numbers of individuals from popu-
lations of non-European ancestry, it is
harder, during diagnostic sequencing of
patients from these populations, to separ-
ate the pathogenic variants from the rare
benign background genetic variation. This
results in patients of non-European ances-
try having longer, less accurate lists of
candidate variants, creating potential
healthcare disparities.11 12
This re-analysis demonstrates that with
periodic assimilation and analysis of new
data, rates of genetic diagnosis with WES
can be substantially >25%–40%, and we
suggest that a multifaceted approach to
re-analysing the WES data should be a
standard part of clinical diagnostic para-
digms. We recognise that our diagnostic
rate of 11/12, with re-analyses over time,
is much higher than one would anticipate.
Our extremely high rate is likely to be
because we carefully selected cases whose
clinical features were strongly suggestive
of Mendelian disorders and excluded
patients with potential non-genetic contri-
butors to disease. Current clinical referrals
for WES likely include patients whose fea-
tures are not as strongly indicative of
Mendelian disorders, and may not have as
clearly ruled out other possible non-
genetic factors. Nonetheless, we believe
that with time and analysis of new data,
rates of diagnosis with WES will continue
to increase within most cohorts.
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